Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Recipient : H3D Foundation
Deal Size : $7.2 million
Deal Type : Series A Financing
LifeArc Makes Investment to Support Drug Discovery in Sub-Saharan Africa
Details : This funding will bolster five drug discovery initiatives in Africa, spanning 3-5 years. H3D Foundation's primary focus lies in addressing life-threatening diseases like malaria and tuberculosis.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 31, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Recipient : H3D Foundation
Deal Size : $7.2 million
Deal Type : Series A Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Recipient : Undisclosed
Deal Size : $6.2 million
Deal Type : Funding
LifeArc Announces £5 million Drug Repurposing Programme for Motor Neuron Disease
Details : The net proceeds will be used to find new treatments for motor neuron disease (MND) as part of a drug repurposing programme to tackle the high failure rate in MND clinical trials.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
December 06, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : Undisclosed
Deal Size : $6.2 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Recipient : Metrion Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration focuses on the discovery of novel selective small molecular modulators of a specific two-pore potassium ion target, identified as likely to be involved in neurological pathogenesis, and has now progressed to the hit-to-lead optimization...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 18, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Recipient : Metrion Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?